Predictive Value of Serum Insulin-like Growth Factor-1 in Hepatocellular Carcinoma

Elmashad, Nehal; Ibrahim, Wesam A.; Mayah, Wael; Farouk, Mohamed; Ali, Lobna Abo; Taha, Atef; Elmashad, Wael

doi:10.7314/apjcp.2015.16.2.613

Cited by 23 publications

(17 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A commonly postulated mechanism is related to the decreased secretion of certain cytokines such as insulin-like growth factor (IGF)-1 from reduced skeletal muscle mass. IGF-1 plays an important role in the growth of various organs, and its decrease in serum was significantly correlated with advanced clinicopathological parameters of HCC [36,37]. Sarcopenia is also linked to several proteolytic cascades such as the tumor necrosis factor (TNF)-α system [38].…”

Section: Discussionmentioning

confidence: 99%

Association between Loss of Skeletal Muscle Mass and Mortality and Tumor Recurrence in Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis

Chang¹,

Chen

Wu³

et al. 2017

Liver Cancer

152

140

View full text Add to dashboard Cite

Background: Hepatocellular carcinoma (HCC) has multiple prognostic factors, and there is an increase in knowledge about the body composition and physical status of patients with HCC. The present meta-analysis aimed to explore whether loss of skeletal muscle mass is associated with mortality and tumor recurrence in patients with HCC. Method: A systematic search was conducted for published literature using PubMed, Embase, and Scopus. We included cohort or case-control studies investigating patients with HCC. The primary and secondary outcomes were the associations of loss of skeletal muscle mass with overall survival and tumor recurrence, respectively, expressed by a summary hazard ratio (HR) and 95% confidence interval (CI). Result: A total of 13 studies comprising 3,111 patients were included. The summary HRs calculated by either univariate or multivariate analysis both suggested a significant association between sarcopenia and all-cause mortality (crude HR = 2.04, 95% CI: 1.74-2.38; adjusted HR = 1.95, 95% CI: 1.60-2.37). Similarly, loss of skeletal muscle mass was associated with tumor recurrence (crude HR = 1.85, 95% CI: 1.44-2.37; adjusted HR = 1.76, 95% CI: 1.27-2.45). The stratified analysis showed that treatment types and inclusion of body mass index or body weight in the Cox regression model did not modify both clinical outcomes. With an increase in cut-off values of muscle mass on computed tomography images (especially for male patients), there was an insignificant trend of stronger associations between loss of skeletal muscle mass and all-cause mortality. Conclusion: Loss of skeletal muscle mass is associated with increased all-cause mortality and tumor recurrence in patients with HCC. Further prospective studies incorporating measurements of muscle strength and physical function are warranted to see whether inclusion of both parameters better predicts the outcome than use of muscle mass only.

show abstract

Section: Discussionmentioning

confidence: 99%

Association between Loss of Skeletal Muscle Mass and Mortality and Tumor Recurrence in Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis

Chang¹,

Chen

Wu³

et al. 2017

Liver Cancer

152

140

View full text Add to dashboard Cite

show abstract

“…It was shown that serum IGF1 levels predict prognosis in cases of HCC. Lower plasma IGF1 levels were significantly correlated with advanced clinical parameters, shorter time to progression and poor overall survival [ 140 , 141 , 145 , 146 , 147 , 148 , 149 ], even in patients that underwent transarterial chemoembolization (TACE) [ 148 , 149 , 150 , 151 , 152 ] or other types of curative treatment, such as surgical resection or percutaneous ethanol injection [ 150 ]. Longitudinal observation of HCC cases (median follow-up period of 41.8 months) proved that IGF1 level was an independent predictor of poorer survival [ 151 ].…”

Section: Evidence From Epidemiologic and Clinicopathological Studimentioning

confidence: 99%

Insulin-Like Growth Factor (IGF) System in Liver Diseases

Adamek

Kasprzak

2018

IJMS

207

149

View full text Add to dashboard Cite

Hepatocyte differentiation, proliferation, and apoptosis are affected by growth factors produced in liver. Insulin-like growth factor 1 and 2 (IGF1 and IGF2) act in response to growth hormone (GH). Other IGF family components include at least six binding proteins (IGFBP1 to 6), manifested by both IGFs develop due to interaction through the type 1 receptor (IGF1R). The data based on animal models and/or in vitro studies suggest the role of IGF system components in cellular aspects of hepatocarcinogenesis (cell cycle progression, uncontrolled proliferation, cell survival, migration, inhibition of apoptosis, protein synthesis and cell growth), and show that systemic IGF1 administration can reduce fibrosis and ameliorate general liver function. In epidemiologic and clinicopathological studies on chronic liver disease (CLD), lowered serum levels, decreased tissue expression of IGF1, elevated production of IGF1R and variable IGF2 expression has been noted, from the start of preneoplastic alterations up to the developed hepatocellular carcinoma (HCC) stage. These changes result in well-known clinical symptoms of IGF1 deficiency. This review summarized the current data of the complex role of IGF system components in the most common CLD (nonalcoholic fatty liver disease, cirrhosis, and hepatocellular carcinoma). Better recognition and understanding of this system can contribute to discovery of new and improved versions of current preventive and therapeutic actions in CLD.

show abstract

“… 136 , 137 , 143 In addition, two recent studies reported that low pretreatment IGF-I levels independently correlated with poor outcome in the form of a shorter TTP and OS in patients with HCC who underwent TACE. 144 , 145 …”

Section: Integrating Igf-i Levels Into Hcc Managementmentioning

confidence: 99%

Type I insulin-like growth factor as a liver reserve assessment tool in hepatocellular carcinoma

Abdel-Wahab

Shehata

Hassan

et al. 2015

JHC

View full text Add to dashboard Cite

Chronic liver diseases (CLDs) encompass a wide range of illnesses, including nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and viral hepatitis. Deterioration of liver capacity, with subsequent progression into cirrhosis and hepatocellular carcinoma (HCC), ultimately leads to a further decrease in the hepatic reserve. The Child–Turcotte–Pugh scoring system is the standard tool for assessing underlying liver reserve capacity in routine practice and in clinical trials of CLD and HCC. In this review, we highlight the clinical significance of insulin-like growth factor-I (IGF-I) and the growth hormone (GH) signaling pathway in HCC. IGF-I could be a marker for liver reserve capacity in CLDs and HCC in clinical practice. This approach could improve the risk assessment and stratifications of patients on the basis of their underlying liver reserve, either before active treatment in routine practice or before they are enrolled in clinical trials.

show abstract

Predictive Value of Serum Insulin-like Growth Factor-1 in Hepatocellular Carcinoma

Cited by 23 publications

References 39 publications

Association between Loss of Skeletal Muscle Mass and Mortality and Tumor Recurrence in Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis

Association between Loss of Skeletal Muscle Mass and Mortality and Tumor Recurrence in Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis

Insulin-Like Growth Factor (IGF) System in Liver Diseases

Type I insulin-like growth factor as a liver reserve assessment tool in hepatocellular carcinoma

Contact Info

Product

Resources

About